Home
CRSP
CRSP News

Latest CRISPR Therapeutics AG (CRSP) News on November 17, 2025

Argus Research

a month ago

Daily – Vickers Top Buyers & Sellers for 10/21/2025

MT Newswires

a month ago

BofA Securities Adjusts Price Target on CRISPR Therapeutics AG to $93 From $78, Maintains Buy Rating

2 Soaring Cathie Wood Stocks to Buy and Hold

Motley Fool

a month ago

2 Soaring Cathie Wood Stocks to Buy and Hold

CRISPR Therapeutics AG (CRSP) Stock Falls Amid Market Uptick: What Investors Need to Know

Zacks

a month ago

CRISPR Therapeutics AG (CRSP) Stock Falls Amid Market Uptick: What Investors Need to Know

A Look at CRISPR Therapeutics’s (CRSP) Valuation Following First Public SyNTase Gene Editing Data Reveal

Simply Wall St.

a month ago

A Look at CRISPR Therapeutics’s (CRSP) Valuation Following First Public SyNTase Gene Editing Data Reveal

3 Growth Stocks That Could Be 10-Baggers in 10 Years

Motley Fool

a month ago

3 Growth Stocks That Could Be 10-Baggers in 10 Years

BMO Reaffirms Outperform on CRISPR Therapeutics (CRSP) After Sirius Collaboration

Insider Monkey

2 months ago

BMO Reaffirms Outperform on CRISPR Therapeutics (CRSP) After Sirius Collaboration

Genome Editing Market Report 2025: CRISPR and Beyond - Emerging Technologies Reshape Biopharmaceutical Landscape

GlobeNewswire

2 months ago

Genome Editing Market Report 2025: CRISPR and Beyond - Emerging Technologies Reshape Biopharmaceutical Landscape

CRISPR Therapeutics to Present Preclinical Data on Alpha-1 Antitrypsin Deficiency (AATD) Utilizing Novel SyNTase Gene Editing Technology at the European Society of Gene and Cell Therapy (ESGCT) 2025 Annual Congress

GlobeNewswire

2 months ago

CRISPR Therapeutics to Present Preclinical Data on Alpha-1 Antitrypsin Deficiency (AATD) Utilizing Novel SyNTase Gene Editing Technology at the European Society of Gene and Cell Therapy (ESGCT) 2025 Annual Congress

H.C. Wainwright Reiterates Buy Rating on CRISPR Therapeutics AG (CRSP) Stock

Insider Monkey

2 months ago

H.C. Wainwright Reiterates Buy Rating on CRISPR Therapeutics AG (CRSP) Stock

3 Promising Genomics & Synthetic Biology Stocks in Spotlight in 2025

Zacks

2 months ago

3 Promising Genomics & Synthetic Biology Stocks in Spotlight in 2025

Global Cell Therapy Market Size Expected to Reach $44 Billion as Demand for Regenerative Medicine Rises

CNW Group

2 months ago

Global Cell Therapy Market Size Expected to Reach $44 Billion as Demand for Regenerative Medicine Rises

MT Newswires

2 months ago

JPMorgan Initiates Coverage on CRISPR Therapeutics With Overweight Rating, $70 Price Target

CRISPR Therapeutics AG (CRSP) Falls More Steeply Than Broader Market: What Investors Need to Know

Zacks

2 months ago

CRISPR Therapeutics AG (CRSP) Falls More Steeply Than Broader Market: What Investors Need to Know

CRISPR (CRSP) Gains Analyst Support on Sales Momentum and Pipeline Expansion

Insider Monkey

2 months ago

CRISPR (CRSP) Gains Analyst Support on Sales Momentum and Pipeline Expansion

Vertex Plunges Around 24% in Six Months: How to Play the Stock

Zacks

2 months ago

Vertex Plunges Around 24% in Six Months: How to Play the Stock

CRISPR Therapeutics (CRSP) Reports Increase In Q2 Revenue Despite Wider Net Losses

Simply Wall St.

3 months ago

CRISPR Therapeutics (CRSP) Reports Increase In Q2 Revenue Despite Wider Net Losses

CRISPR Therapeutics Gains 41.4% in 3 Months: How to Play the Stock

Zacks

3 months ago

CRISPR Therapeutics Gains 41.4% in 3 Months: How to Play the Stock

CRISPR Therapeutics (NasdaqGM:CRSP) Announces Promising Data From Cardiovascular Disease Programs

Simply Wall St.

5 months ago

CRISPR Therapeutics (NasdaqGM:CRSP) Announces Promising Data From Cardiovascular Disease Programs

MT Newswires

5 months ago

CRISPR Therapeutics Advances Phase 1 Trials for Cardiovascular Disease Programs

CRISPR Therapeutics Reports Positive Additional Phase 1 Data for CTX310™ Targeting ANGPTL3 and Provides Update on In Vivo Cardiovascular Pipeline

GlobeNewswire

5 months ago

CRISPR Therapeutics Reports Positive Additional Phase 1 Data for CTX310™ Targeting ANGPTL3 and Provides Update on In Vivo Cardiovascular Pipeline

CRISPR Therapeutics AG (CRSP) Stock Moves 1.88%: What You Should Know

Zacks

5 months ago

CRISPR Therapeutics AG (CRSP) Stock Moves 1.88%: What You Should Know

CRISPR Therapeutics vs. Intellia: Which Gene Editing Stock Holds More Potential?

Zacks

5 months ago

CRISPR Therapeutics vs. Intellia: Which Gene Editing Stock Holds More Potential?

CRISPR Therapeutics AG (CRSP) Surpasses Market Returns: Some Facts Worth Knowing

Zacks

5 months ago

CRISPR Therapeutics AG (CRSP) Surpasses Market Returns: Some Facts Worth Knowing

CRISPR Therapeutics AG (CRSP): A Bull Case Theory

Insider Monkey

5 months ago

CRISPR Therapeutics AG (CRSP): A Bull Case Theory

Is CRISPR Therapeutics AG (NASDAQ:CRSP) Trading At A 45% Discount?

Simply Wall St.

5 months ago

Is CRISPR Therapeutics AG (NASDAQ:CRSP) Trading At A 45% Discount?

2 Biotech Stocks to Buy Before They Soar 84% and 240%, According to Certain Wall Street Analysts

Motley Fool

5 months ago

2 Biotech Stocks to Buy Before They Soar 84% and 240%, According to Certain Wall Street Analysts

The FDA Shake-Up Continues, And Could Impact Genetic Medicines

Investor's Business Daily

5 months ago

The FDA Shake-Up Continues, And Could Impact Genetic Medicines

Cathie Wood's Flagship Ark Innovation ETF Is Booming Again. Here's Why.

Investor's Business Daily

5 months ago

Cathie Wood's Flagship Ark Innovation ETF Is Booming Again. Here's Why.

Can Casgevy Deliver a Turnaround for CRISPR Therapeutics?

Zacks

5 months ago

Can Casgevy Deliver a Turnaround for CRISPR Therapeutics?

CRISPR Therapeutics AG (CRSP) Increases Despite Market Slip: Here's What You Need to Know

Zacks

5 months ago

CRISPR Therapeutics AG (CRSP) Increases Despite Market Slip: Here's What You Need to Know

Gene-Editing Stocks Gain on LLY-VERV Deal Announcement

Zacks

5 months ago

Gene-Editing Stocks Gain on LLY-VERV Deal Announcement

CRISPR Therapeutics AG (CRSP) Is a Trending Stock: Facts to Know Before Betting on It

Zacks

5 months ago

CRISPR Therapeutics AG (CRSP) Is a Trending Stock: Facts to Know Before Betting on It

Verve Therapeutics Skyrockets — Pulling Gene-Editing Stocks Higher — On $1.3 Billion Eli Lilly Takeover

Investor's Business Daily

5 months ago

Verve Therapeutics Skyrockets — Pulling Gene-Editing Stocks Higher — On $1.3 Billion Eli Lilly Takeover

CRISPR Therapeutics Gains 14% in a Month: How to Play the Stock?

Zacks

5 months ago

CRISPR Therapeutics Gains 14% in a Month: How to Play the Stock?

CRISPR Therapeutics AG (CRSP) Rises Higher Than Market: Key Facts

Zacks

5 months ago

CRISPR Therapeutics AG (CRSP) Rises Higher Than Market: Key Facts

CRISPR Therapeutics (NasdaqGM:CRSP) Sees 16% Stock Price Surge Over Last Month

Simply Wall St.

5 months ago

CRISPR Therapeutics (NasdaqGM:CRSP) Sees 16% Stock Price Surge Over Last Month

Morningstar Research

5 months ago

Morningstar | A Weekly Summary of Stock Ideas and Developments in the Companies We Cover

Investors Heavily Search CRISPR Therapeutics AG (CRSP): Here is What You Need to Know

Zacks

5 months ago

Investors Heavily Search CRISPR Therapeutics AG (CRSP): Here is What You Need to Know

Morningstar Research

5 months ago

Analyst Report: CRISPR Therapeutics AG

CRISPR Therapeutics (CRSP) Up 11.1% Since Last Earnings Report: Can It Continue?

Zacks

5 months ago

CRISPR Therapeutics (CRSP) Up 11.1% Since Last Earnings Report: Can It Continue?

BEAM Up on FDA's Orphan Drug Status for Gene-Editing Therapy

Zacks

5 months ago

BEAM Up on FDA's Orphan Drug Status for Gene-Editing Therapy

Can CRISPR Build on Casgevy's Success With Its In Vivo Pipeline?

Zacks

5 months ago

Can CRISPR Build on Casgevy's Success With Its In Vivo Pipeline?

The Best Stocks to Invest $1,000 in Right Now

Motley Fool

5 months ago

The Best Stocks to Invest $1,000 in Right Now

The 2 Smartest Beaten-Down Biotech Stocks to Buy on the Dip

Motley Fool

5 months ago

The 2 Smartest Beaten-Down Biotech Stocks to Buy on the Dip

CRISPR Therapeutics to Participate in Upcoming Investor Conferences

GlobeNewswire

6 months ago

CRISPR Therapeutics to Participate in Upcoming Investor Conferences

CRISPR Therapeutics AG (CRSP) is Attracting Investor Attention: Here is What You Should Know

Zacks

6 months ago

CRISPR Therapeutics AG (CRSP) is Attracting Investor Attention: Here is What You Should Know

Crispr Therapeutics call volume above normal and directionally bullish

TipRanks

6 months ago

Crispr Therapeutics call volume above normal and directionally bullish

3 Top Genomics Stocks to Add to Your Portfolio in 2025

Zacks

6 months ago

3 Top Genomics Stocks to Add to Your Portfolio in 2025

MT Newswires

6 months ago

Mizuho Cuts Price Target on CRISPR Therapeutics to $85 From $99, Keeps Outperform Rating

CRISPR Therapeutics AG (CRSP) Strikes $95M Deal with Sirius to Develop Blood Clot Drug

Insider Monkey

6 months ago

CRISPR Therapeutics AG (CRSP) Strikes $95M Deal with Sirius to Develop Blood Clot Drug

CRISPR Therapeutics Inks Collaboration Deal to Develop siRNA Therapies

Zacks

6 months ago

CRISPR Therapeutics Inks Collaboration Deal to Develop siRNA Therapies

5 Monster Stocks to Hold for the Next 10 Years

Motley Fool

6 months ago

5 Monster Stocks to Hold for the Next 10 Years

CRISPR Therapeutics Stock Could Double Your Money, According to Wall Street. Is It Time to Buy?

Motley Fool

6 months ago

CRISPR Therapeutics Stock Could Double Your Money, According to Wall Street. Is It Time to Buy?

MT Newswires

6 months ago

CRISPR, Sirius Collaborate on RNA Therapy Targeting Blood Clot Disorders

CRISPR Therapeutics and Sirius Therapeutics Announce Multi-Target Collaboration to Develop Novel siRNA Therapies

GlobeNewswire

6 months ago

CRISPR Therapeutics and Sirius Therapeutics Announce Multi-Target Collaboration to Develop Novel siRNA Therapies

Prediction: This Beaten-Down Stock Could Double in The Next 5 Years

Motley Fool

6 months ago

Prediction: This Beaten-Down Stock Could Double in The Next 5 Years

Are Investors Making a Big Mistake Dumping Shares of CRISPR Therapeutics?

Motley Fool

6 months ago

Are Investors Making a Big Mistake Dumping Shares of CRISPR Therapeutics?

CRISPR Therapeutics AG (CRSP) Is a Trending Stock: Facts to Know Before Betting on It

Zacks

6 months ago

CRISPR Therapeutics AG (CRSP) Is a Trending Stock: Facts to Know Before Betting on It

2 Biotech Stocks That Are Screaming Buys in May

Motley Fool

6 months ago

2 Biotech Stocks That Are Screaming Buys in May

Can Buying CRISPR Therapeutics and Holding It Forever Make You a Millionaire?

Motley Fool

6 months ago

Can Buying CRISPR Therapeutics and Holding It Forever Make You a Millionaire?

3 Monster Stocks to Hold for the Next 10 Years

Motley Fool

6 months ago

3 Monster Stocks to Hold for the Next 10 Years

CRISPR Therapeutics (NasdaqGM:CRSP) Q1 2025 Revenue Increases 71% to US$1 Million

Simply Wall St.

6 months ago

CRISPR Therapeutics (NasdaqGM:CRSP) Q1 2025 Revenue Increases 71% to US$1 Million

Cathie Wood Goes Bargain Hunting: 3 Stocks She Just Bought

Motley Fool

6 months ago

Cathie Wood Goes Bargain Hunting: 3 Stocks She Just Bought

Brokers Suggest Investing in CRISPR Therapeutics (CRSP): Read This Before Placing a Bet

Zacks

6 months ago

Brokers Suggest Investing in CRISPR Therapeutics (CRSP): Read This Before Placing a Bet

CRISPR Therapeutics First Quarter 2025 Earnings: Misses Expectations

Simply Wall St.

6 months ago

CRISPR Therapeutics First Quarter 2025 Earnings: Misses Expectations

CRISPR Therapeutics Q1 Earnings and Sales Miss Estimates, Stock Tanks

Zacks

6 months ago

CRISPR Therapeutics Q1 Earnings and Sales Miss Estimates, Stock Tanks

We're Not Very Worried About CRISPR Therapeutics' (NASDAQ:CRSP) Cash Burn Rate

Simply Wall St.

6 months ago

We're Not Very Worried About CRISPR Therapeutics' (NASDAQ:CRSP) Cash Burn Rate

CRISPR Therapeutics AG (CRSP) Reports Q1 Loss, Misses Revenue Estimates

Zacks

6 months ago

CRISPR Therapeutics AG (CRSP) Reports Q1 Loss, Misses Revenue Estimates

CRISPR Therapeutics Provides First Quarter 2025 Financial Results and Announces Positive Top-Line Data from Phase 1 Clinical Trial of CTX310™ Targeting ANGPTL3

GlobeNewswire

6 months ago

CRISPR Therapeutics Provides First Quarter 2025 Financial Results and Announces Positive Top-Line Data from Phase 1 Clinical Trial of CTX310™ Targeting ANGPTL3

Liquidia Technologies (LQDA) Surges 13.2%: Is This an Indication of Further Gains?

Zacks

6 months ago

Liquidia Technologies (LQDA) Surges 13.2%: Is This an Indication of Further Gains?

CRISPR Therapeutics AG (CRSP) Advances But Underperforms Market: Key Facts

Zacks

6 months ago

CRISPR Therapeutics AG (CRSP) Advances But Underperforms Market: Key Facts

CRISPR Therapeutics AG (CRSP) is Attracting Investor Attention: Here is What You Should Know

Zacks

6 months ago

CRISPR Therapeutics AG (CRSP) is Attracting Investor Attention: Here is What You Should Know

2 Beaten-Down Stocks With Incredible Upside Potential

Motley Fool

7 months ago

2 Beaten-Down Stocks With Incredible Upside Potential

CRISPR Therapeutics to Report Q1 Earnings: What's in the Cards?

Zacks

7 months ago

CRISPR Therapeutics to Report Q1 Earnings: What's in the Cards?

CRISPR Therapeutics AG (CRSP) Advances But Underperforms Market: Key Facts

Zacks

7 months ago

CRISPR Therapeutics AG (CRSP) Advances But Underperforms Market: Key Facts

Morningstar Research

7 months ago

Analyst Report: CRISPR Therapeutics AG

CRISPR Therapeutics AG (CRSP) Stock Falls Amid Market Uptick: What Investors Need to Know

Zacks

7 months ago

CRISPR Therapeutics AG (CRSP) Stock Falls Amid Market Uptick: What Investors Need to Know

‘Incoming Regulatory Tailwinds’ to Spur 90% Upside for CRISPR Therapeutics Stock, Says BMO Capital

TipRanks

7 months ago

‘Incoming Regulatory Tailwinds’ to Spur 90% Upside for CRISPR Therapeutics Stock, Says BMO Capital

CRISPR Therapeutics AG (CRSP) Is a Trending Stock: Facts to Know Before Betting on It

Zacks

7 months ago

CRISPR Therapeutics AG (CRSP) Is a Trending Stock: Facts to Know Before Betting on It

CRISPR Therapeutics AG (CRSP) Stock Slides as Market Rises: Facts to Know Before You Trade

Zacks

7 months ago

CRISPR Therapeutics AG (CRSP) Stock Slides as Market Rises: Facts to Know Before You Trade

MT Newswires

7 months ago

BofA Adjusts Price Target on CRISPR Therapeutics to $80 From $86, Keeps Buy Rating

CRISPR Therapeutics (NasdaqGM:CRSP) Sees 25% Price Increase Over Last Week

Simply Wall St.

7 months ago

CRISPR Therapeutics (NasdaqGM:CRSP) Sees 25% Price Increase Over Last Week

3 Magnificent Stocks That Could Double or More by 2030

Motley Fool

7 months ago

3 Magnificent Stocks That Could Double or More by 2030

Could CRISPR Therapeutics Become the Next Vertex Pharmaceuticals?

Motley Fool

7 months ago

Could CRISPR Therapeutics Become the Next Vertex Pharmaceuticals?

CRISPR Therapeutics AG (CRSP) Stock Moves -1.81%: What You Should Know

Zacks

7 months ago

CRISPR Therapeutics AG (CRSP) Stock Moves -1.81%: What You Should Know

CRISPR Therapeutics AG (CRSP) is Attracting Investor Attention: Here is What You Should Know

Zacks

7 months ago

CRISPR Therapeutics AG (CRSP) is Attracting Investor Attention: Here is What You Should Know

4 Beaten-Down Stocks That Could Skyrocket by 50% to 543%, According to Wall Street

Motley Fool

7 months ago

4 Beaten-Down Stocks That Could Skyrocket by 50% to 543%, According to Wall Street

Cathie Wood Goes Bargain Hunting: 3 Stocks She Just Bought

Motley Fool

7 months ago

Cathie Wood Goes Bargain Hunting: 3 Stocks She Just Bought

CRISPR Therapeutics (NasdaqGM:CRSP) Sees 12% Weekly Dip Following COO Resignation

Simply Wall St.

7 months ago

CRISPR Therapeutics (NasdaqGM:CRSP) Sees 12% Weekly Dip Following COO Resignation

CRISPR Therapeutics AG (CRSP) Stock Moves -0.03%: What You Should Know

Zacks

7 months ago

CRISPR Therapeutics AG (CRSP) Stock Moves -0.03%: What You Should Know

Why Biotech Stocks Such as Biohaven, Recursion Pharmaceuticals, and CRISPR Therapeutics Plunged in March

Motley Fool

7 months ago

Why Biotech Stocks Such as Biohaven, Recursion Pharmaceuticals, and CRISPR Therapeutics Plunged in March

CRISPR Therapeutics to Present at the 24th Annual Needham Virtual Healthcare Conference

GlobeNewswire

7 months ago

CRISPR Therapeutics to Present at the 24th Annual Needham Virtual Healthcare Conference

MT Newswires

7 months ago

RBC Cuts Price Target on CRISPR Therapeutics to $38 From $48, Keeps Sector Perform, Speculative Risk

Biotech stocks slide as Marks resignation seen being negative for sector

TipRanks

8 months ago

Biotech stocks slide as Marks resignation seen being negative for sector

Biotechs Hammered After FDA Official Resigns, Citing RFK Jr.'s 'Misinformation And Lies'

Investor's Business Daily

8 months ago

Biotechs Hammered After FDA Official Resigns, Citing RFK Jr.'s 'Misinformation And Lies'

Why Biotech Stocks Like Recursion Pharmaceuticals, CRISPR Therapeutics, and Summit Therapeutics Plunged Today

Motley Fool

8 months ago

Why Biotech Stocks Like Recursion Pharmaceuticals, CRISPR Therapeutics, and Summit Therapeutics Plunged Today

Intellia Focuses on Pipeline Development Amid Stiff Competition

Zacks

8 months ago

Intellia Focuses on Pipeline Development Amid Stiff Competition

Moderna, Vaxcyte, Novavax Hammered After Key FDA Official Peter Marks Resigns

Investor's Business Daily

8 months ago

Moderna, Vaxcyte, Novavax Hammered After Key FDA Official Peter Marks Resigns

The Zacks Analyst Blog Highlights Illumina, BEAM, Twist Bioscience, Wave Life Sciences and CRISPR Therapeutics

Zacks

8 months ago

The Zacks Analyst Blog Highlights Illumina, BEAM, Twist Bioscience, Wave Life Sciences and CRISPR Therapeutics

Share on Social Networks: